Dick Pluim

A Phase I and Pharmacological Study with Imidazolium-<b> <i>trans-</i> </b>DMSO-imidazole-tetrachlororuthenate, a Novel Ruthenium Anticancer Agent

Jeany M. Rademaker-Lakhai, H.J.G.D. van den Bongard, Dick Pluim et al. · Clinical Cancer Research · 2004 · 820 citations · Full text

Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line.

Marc Maliepaard, M A van Gastelen, L A de Jong et al. · PubMed · 1999 · 487 citations

Chemoprevention Strategy, Pathology, Cancer Biology +18

Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy

Suzanne Leijen, Sjaak A. Burgers, Paul Baas et al. · Investigational New Drugs · 2014 · 365 citations · Full text

Oncology, Phase I/ii Study, Medicine +10

The Effect of Bcrp1 (Abcg2) on the <i>In vivo</i> Pharmacokinetics and Brain Penetration of Imatinib Mesylate (Gleevec): Implications for the Use of Breast Cancer Resistance Protein and P-Glycoprotein Inhibitors to Enable the Brain Penetration of Imatinib in Patients

Pauline Breedveld, Dick Pluim, Greta Cipriani et al. · Cancer Research · 2005 · 349 citations

Brain Penetration, Pharmacotherapy, Glioma +16

Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With <i>TP53</i>-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months

Suzanne Leijen, Robin M.J.M. van Geel, Gabe S. Sonke et al. · Journal of Clinical Oncology · 2016 · 328 citations · Full text

Tumor Biology, Purpose Azd1775, Medicine +15